NEW YORK, February 23, 2023: Morgan Lewis is representing MEI Pharma Inc. in a definitive merger agreement with Infinity Pharmaceuticals Inc. for an all-stock transaction, forming a new company to advance three clinical-stage oncology drug candidates.
MEI Pharma is a clinical-stage pharmaceutical company focused on advancing new therapies for cancer. Infinity Pharmaceuticals is a clinical-stage biotechnology company developing eganelisib, an oral, immuno-oncology macrophage reprogramming drug candidate.
Morgan Lewis partners Steven Navarro and Robert Dickey, and associates Samuel Worth and Fannie Law are advising MEI Pharma.